Article | June 5, 2023

Integrated Annex 1 Compliance – The Impact On Parenteral Filling, Cleanrooms, And Robotics

Source: Dec Group

By Declan O’Shea

GettyImages-1370928101 data compliance

The recent changes to EU GMP Annex 1 display a more serious approach to the filling of parenteral drug products and the quality assurance expected for those products administered into both human beings and animals. With any change in regulation comes the eventual need for compliance. In order to meet new auditing requirements, in line with the new Annex 1 document, changes will need to be made in both the areas of the drug manufacturing process as well as the equipment required to support that process.

Learn about the critical changes in the Annex 1 guidance from a process equipment provider's perspective, several areas where process and product change could take place, and more.

access the Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Pharmaceutical Online? Subscribe today.

Subscribe to Pharmaceutical Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Pharmaceutical Online